Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Corcept Therapeutics (CORT) over the last 10 years, with Q3 2025 value amounting to $5.1 million.

  • Corcept Therapeutics' Change in Receivables fell 1391.16% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year decrease of 6049.58%. This contributed to the annual value of $12.9 million for FY2024, which is 2768.73% up from last year.
  • Latest data reveals that Corcept Therapeutics reported Change in Receivables of $5.1 million as of Q3 2025, which was down 1391.16% from $2.7 million recorded in Q2 2025.
  • Corcept Therapeutics' 5-year Change in Receivables high stood at $20.4 million for Q1 2024, and its period low was -$7.7 million during Q2 2024.
  • Moreover, its 5-year median value for Change in Receivables was $1.5 million (2023), whereas its average is $2.3 million.
  • Within the past 5 years, the most significant YoY rise in Corcept Therapeutics' Change in Receivables was 125966.67% (2024), while the steepest drop was 19192500.0% (2024).
  • Corcept Therapeutics' Change in Receivables (Quarter) stood at $1.1 million in 2021, then skyrocketed by 47.09% to $1.6 million in 2022, then surged by 295.44% to $6.5 million in 2023, then tumbled by 188.36% to -$5.7 million in 2024, then skyrocketed by 188.17% to $5.1 million in 2025.
  • Its last three reported values are $5.1 million in Q3 2025, $2.7 million for Q2 2025, and $7.8 million during Q1 2025.